IMS Reports AbbVie (ABBV) Viekira Pak Week 1 Scripts (GILD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to IMS Reports AbbVie (ABBV) Viekira Pak Week 1 Scripts (GILD)

AbbVie (ABBV), BioPharma's on Watch; Gilead's Havroni Receives Preferred Status at CVS (AMGN)

January 5, 2015 11:53 AM EST

AbbVie (NYSE: ABBV) shares are active following news that Gilead's (Nasdaq: GILD) Havroni received preferred formulary status by CVS Health.

Other biopharma's on watch: Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), BioMarin Pharma (NASDAQ: BMRN), Celgene (NASDAQ: CELG),, Incyte (NASDAQ: INCY), and Pharmacyclics (NASDAQ: PCYC).

... More

Gilead Sciences (GILD) PT Trimmed to $146 at Nomura; 'Buy' Maintained

January 5, 2015 11:02 AM EST

Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating but lowered his price target on Gilead Sciences (NASDAQ: GILD) to $146.00 (from $152.00).

The lowered price target accounts for more aggressive discounting from AbbVie and Express Scripts agreement.

For an analyst ratings... More

RBC Outlines What to Expect Ahead of Initial AbbVie (ABBV) Viekira Pak Scripts (GILD)

December 31, 2014 5:57 AM EST

RBC Capital offered commentary on Gilead Sciences (Nasdaq: GILD) ahead of AbbVie (NYSE: ABBV) prescription data, which could be made available this Friday (January 2nd).

Analyst Michael Yee sees initial Viekira Pak scripts being small given the holiday week, but expects a gradual pickup... More